The FDA issued two Warning Letters for undeclared allergens and the introduction or delivery for introduction into interstate commerce of any food that is misbranded which is prohibited by section 301(a) of the FD&C Act to Hanover Foods and George DeLallo Company.
Share:
New York, May 03, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Diuretics Global Market Report 2021: COVID 19 Impact and Recovery to 2030 - https://www.reportlinker.com/p06067865/?utm source=GNW
91 billion in 2021 at a compound annual growth rate (CAGR) of 11%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.18 billion in 2025 at a CAGR of 6.7%.
The diuretic drugs market consists of sales of diuretic drugs and related services.Diuretic drugs help increase the flow of urine by reducing concentration of sodium and chloride in the body.
Farlong Pharmaceutical Celebrates Women’s Health Month and Mother’s Day with Special Promotion
Share Article
Nutraceuticals Company Offering 20% Off Top-Selling Supplements for Women including Heart Advanced Support, JointEase with UC-II® and InnerPure® Colon Detox through May 15
Farlong’s Heart Advanced Support WALNUT, Calif. (PRWEB) May 03, 2021
Farlong Pharmaceutical, a vertically integrated, plant-based ingredient and supplement company, is offering 20% off top selling products for women including Heart Advanced Support containing Ginseng Plus® Panax Notoginseng™ extract, JointEase with UC-II® and InnerPure® Colon Detox through May 15 in honor of Women’s Health Month this May and Mother’s Day.
Recognized for promoting cardiovascular health and optimal physical performance, Farlong’s Heart Advanced Support utilizes Ginseng Plus® Panax Notoginseng™ extract that has been proven to deliver
ACI, CHPA Urge FDA: Withdraw Allowance for Emergency Sanitizer Production April 30, 2021 Contact Author Rachel Grabenhofer
Close
Sponsored
In an appeal to the U.S. Food and Drug Administration (FDA), the American Cleaning Institute (ACI) and Consumer Healthcare Products Association (CHPA) urged the agency to withdraw its emergency guidance allowing non-traditional manufacturers to produce hand sanitizers, citing safety concerns.
The ACI and CHPA wrote, In the early days of the COVID-19 pandemic, FDA issued its Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19), to help meet unprecedented demand, allowing non-traditional sanitizer companies to manufacture these FDA-regulated products. While FDA’s temporary guidance provides instructions for developing hand sanitizers, the newer manufacturers were not required to meet FDA’s typical manufacturing requirements which
MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs
April 28, 2021 10:21 ET | Source: MiMedx Group, Inc MiMedx Group, Inc
Accomplished Regulatory Leader Joins MiMedx Management Team
MARIETTA, Ga., April 28, 2021 (GLOBE NEWSWIRE) MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the addition of Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs, effective May 3, 2021. Dr. Stevens, who brings more than 35 years of strategic leadership experience in quality management and regulatory compliance across multiple medical device and pharmaceutical companies, joins MiMedx from Smith & Nephew, plc, where he was accountable for regulatory submissions, compliance, and Commercial Quality Assurance.